Duodenal & gastric ulcer; moderate & severe reflux esophagitis; Zollinger-Ellison syndrome & other pathological hypersecretory conditions.
Dosage/Direction for Use
Duodenal & gastric ulcer, moderate & severe reflux esophagitis 40 mg/day IV. Zollinger-Ellison syndrome & other pathological hypersecretory conditions Initially 80 mg/day IV, may be titrated up or down as needed w/ doses >80 mg given bid.
Hypersensitivity to pantoprazole, substituted benzimidazoles.
Significant unintentional wt loss, recurrent vomiting, dysphagia, haematemesis, anemia or melaena. Exclude possibility of malignancy prior to treatment of gastric ulcer.
Fatigue, asthenia, increased sweating; headache; diarrhoea, severe eructation, constipaton or flatulence, dry mouth, upper abdominal pain.